top of page

Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC

  • Dec 16, 2024
  • 1 min read

He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next year. Plus, where Cardiff believes it can go beyond colorectal cancer with this asset.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page